MedTrace Logo

Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis

NCT03092154 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-06-03

No results posted yet for this study

Summary

The use of lipid lowering agents in patients with idiopathic inflammatory myopathies is controversial. Therefore, the aim of the present study is to assess clinically and laboratory the impact of lipid-lowering agents in this population.

Conditions

  • Treatment Side Effects

Interventions

DRUG

Lipid-lowering agents (Artovastatin)

Artovastatin 20 mg /day, orally, 12 consecutive weeks.

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Samuel K Shinjo, PhD · Universidade de Sao Paulo - Rheumatology Division

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03092154 on ClinicalTrials.gov